Referenties

Duh, M.S., Cahill, K.E., Paradis, P.E., Cremieux, P.Y., Greenberg, P.E. (2009). The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence. Expert Opin. Pharmacother. 10, 2317-2328.

Kesselheim, A.S., Stedman, M.R., Bubrick, E.J., Gagne, J.J., Misono, A.S., Lee, J.L., Brookhart, M.A., Avorn, J., Shrank, W.H. (2010). Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs 70, 605-21.

Kesselheim, A. S., Bykov, K., Gagne, J. J., Wang, S. V., & Choudhry, N. K. (2016). Switching generic antiepileptic drug manufacturer not linked to seizures: A case-crossover study. Neurology, 87(17), 1796-1801. doi: 10.1212/wnl.0000000000003259

KNMP (Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie). (2013) Handeleiding Geneesmiddelensubstitutie. Den Haag: KNMP Geneesmiddel Informatie Centrum.

Liow, K., Barkley, G.L.,  Pollard, J.R., Harden, C.L., Bazil, C.W. (2007). Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology 68;1249-1250.

National Institute for Health and Clinical Excellence (NICE). (2012). The Epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care, Nice Clinical Guideline 137. London: National Institute for Health and Clinical Excellence.

Perucca, E., Albani, F., Capovilla, G., Dalla Bernardina, B., Michelucci,R., Zaccara, G. (2006). Recommendations of the Italian League Against Epilepsy Working Group on Generic Products of Antiepileptic Drugs. Epilepsia, 47(Suppl. 5), 16–20.

Yamada, M., Welty, T.E. (2011). Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies. Ann. Pharmacother. 45, 1406-15.